Effectiveness of Adding Antiplatelets to Oral Anticoagulants in Patients with Acute Ischemic Stroke with Atrial Fibrillation and Concomitant Large Artery Steno-Occlusion
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Joon-Tae | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Kang, Kyusik | - |
dc.contributor.author | Lee, Soo Joo | - |
dc.contributor.author | Kim, Jae Guk | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Kim, Dae-Hyun | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Park, Sang-Soon | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Cho, Yong-Jin | - |
dc.contributor.author | Park, Hong-Kyun | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Oh, Mi Sun | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Ryu, Wi-Sun | - |
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Kwon, Jee-Hyun | - |
dc.contributor.author | Kim, Wook-Joo | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Sohn, Sung Il | - |
dc.contributor.author | Hong, Jeong-Ho | - |
dc.contributor.author | Park, Man-Seok | - |
dc.contributor.author | Choi, Kang-Ho | - |
dc.contributor.author | Cho, Ki-Hyun | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Gorelick, Philip B. | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.date.accessioned | 2021-08-30T07:12:03Z | - |
dc.date.available | 2021-08-30T07:12:03Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 1868-4483 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/51403 | - |
dc.description.abstract | We investigated the effectiveness of adding antiplatelet (AP) to oral anticoagulant (OAC) treatment versus OAC treatment alone in patients with AIS with atrial fibrillation (AF) and significant large artery steno-occlusion (LASO). This study is a retrospective analysis of a nationwide, prospective, multicenter stroke registry between April 2008 and November 2017. Patients with acute (within 48 h of onset) and mild-to-moderate (NIHSS score <= 15) stroke with AF and concomitant LASO were identified. Antithrombotic regimens at discharge were categorized into OAC alone or OAC + AP. The primary outcome event was a composite of recurrent stroke, myocardial infarction, and all-cause mortality within 3 months of stroke. Among the 2553 patients (age, 73 +/- 10 years; men, 50.4%), 78.8% were treated with OAC alone, and 21.2% were treated with OAC + AP. The primary outcome events were significantly more common in the OAC + AP group (6.7%) than the OAC alone group (4.3%) (p = 0.02). Weighted Cox proportional hazard analysis showed that OAC + AP increased the risk of 3-month primary outcome events compared with OAC alone (HR, 1.62 [1.06 to 2.46]). A potential interaction between the type of LASO and discharge antithrombotics was suggested (P-interaction = 0.04); unlike in patients with complete occlusion (OAC + AP; HR, 2.00 [1.27-3.15]), OAC + AP was comparable with OAC alone for 3-month primary outcome in patients with moderate-to-severe stenosis (HR, 0.54 [0.17-1.70]). In conclusion, OAC + AP might increase the risk of 3-month outcome events compared with OAC alone in patients with AIS with AF and concomitant LASO. However, the effect of additional AP to OAC might differ according to LASO type. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | RISK-FACTORS | - |
dc.subject | ASPIRIN | - |
dc.subject | PREVENTION | - |
dc.subject | THERAPY | - |
dc.subject | PREVALENCE | - |
dc.subject | GUIDELINES | - |
dc.subject | MECHANISMS | - |
dc.subject | WARFARIN | - |
dc.title | Effectiveness of Adding Antiplatelets to Oral Anticoagulants in Patients with Acute Ischemic Stroke with Atrial Fibrillation and Concomitant Large Artery Steno-Occlusion | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1007/s12975-020-00822-z | - |
dc.identifier.scopusid | 2-s2.0-85085886956 | - |
dc.identifier.wosid | 000560578300001 | - |
dc.identifier.bibliographicCitation | TRANSLATIONAL STROKE RESEARCH, v.11, no.6, pp.1322 - 1331 | - |
dc.relation.isPartOf | TRANSLATIONAL STROKE RESEARCH | - |
dc.citation.title | TRANSLATIONAL STROKE RESEARCH | - |
dc.citation.volume | 11 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1322 | - |
dc.citation.endPage | 1331 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Large artery steno-occlusion | - |
dc.subject.keywordAuthor | Oral anticoagulant | - |
dc.subject.keywordAuthor | Antiplatelet | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.